Orion Portfolio Solutions’s Neurogene NGNE Stock Holding History

Orion Portfolio Solutions’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-559	Closed	-$12K	–	744
2022 Q2	$12K	Buy	+559	New	+$13.6K	﹤0.01%	676

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Orion Portfolio Solutions's NGNE Position: Q3 2022 in Review

Orion Portfolio Solutions sold out of Neurogene (NGNE) in Q3 2022, closing a stake of 559 shares — an estimated $12K sold.

Orion Portfolio Solutions first reported a position in NGNE in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

Orion Portfolio Solutions reported no remaining Neurogene position as of Q3 2022 after selling out during the quarter.
Orion Portfolio Solutions sold 559 Neurogene shares in Q3 2022, an estimated $12K.
Orion Portfolio Solutions first reported a position in Neurogene in Q2 2022 and held it in 1 quarter.
Orion Portfolio Solutions's Neurogene position peaked at $12K in Q2 2022.
52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on Orion Portfolio Solutions's 13F filing for Q3 2022, filed 9 Nov 2022.